[A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion].
Identifieur interne : 001874 ( PubMed/Corpus ); précédent : 001873; suivant : 001875[A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion].
Auteurs : Atsuko Jinnai ; Tomoko Kikuchi ; Motonao Ishikawa ; Yoshiko Nishimura ; Koichi Shibata ; Hiroshi SakuraSource :
- Rinsho shinkeigaku = Clinical neurology [ 1882-0654 ] ; 2014.
English descriptors
- KwdEn :
- Acyclovir (administration & dosage), Adult, Antibodies, Viral (blood), Antibodies, Viral (cerebrospinal fluid), Antiviral Agents (administration & dosage), Biomarkers (blood), Biomarkers (cerebrospinal fluid), Corpus Callosum (pathology), Diffusion Magnetic Resonance Imaging, Encephalitis (drug therapy), Encephalitis (etiology), Encephalitis (immunology), Encephalitis, Viral (complications), Encephalitis, Viral (diagnosis), Encephalitis, Viral (drug therapy), Encephalitis, Viral (pathology), Humans, Immunoenzyme Techniques, Immunoglobulin M (blood), Immunoglobulin M (cerebrospinal fluid), Infusions, Intravenous, Male, Rubella (complications), Rubella (diagnosis), Rubella (drug therapy), Rubella (pathology), Rubella virus (immunology), Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Acyclovir, Antiviral Agents.
- chemical , blood : Antibodies, Viral, Biomarkers, Immunoglobulin M.
- chemical , cerebrospinal fluid : Antibodies, Viral, Biomarkers, Immunoglobulin M.
- complications : Encephalitis, Viral, Rubella.
- diagnosis : Encephalitis, Viral, Rubella.
- drug therapy : Encephalitis, Encephalitis, Viral, Rubella.
- etiology : Encephalitis.
- immunology : Encephalitis, Rubella virus.
- pathology : Corpus Callosum, Encephalitis, Viral, Rubella.
- Adult, Diffusion Magnetic Resonance Imaging, Humans, Immunoenzyme Techniques, Infusions, Intravenous, Male, Severity of Illness Index, Treatment Outcome.
Abstract
A 26-year-old male was admitted because of a fever, headache and disturbance of consciousness with lymph node swelling of the neck two days after developing a rash. A neurological examination revealed restlessness with irritability in response to sensory stimuli, such as an injection. Diffusion-weighted brain magnetic resonance imaging (MRI) revealed a hyperintense ovoid lesion in the splenium of the corpus callosum, which showed a low coefficient in the ADC map: the lesion disappeared after 22 days. An enzyme immunoassay (EIA) of the serum and cerebrospinal IgM were positive for rubella virus. The patient was therefore diagnosed with rubella encephalitis. He recovered gradually and was discharged on day 19 after the onset of symptoms without any sequelae. To our knowledge, this is the first case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). Although the exact mechanism underlying the development of rubella encephalitis is not well established, this case indicated that our patient had an immune-mediated secondary encephalitis. According to the survey of the pandemic of rubella from 2012 to April 2013 in Japan, the incidence of rubella encephalitis is thought to be relatively higher than was previously noted. This emphasizes the importance of vaccination for preventing encephalitis.
DOI: 10.5692/clinicalneurol.54.668
PubMed: 25142541
Links to Exploration step
pubmed:25142541Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion].</title><author><name sortKey="Jinnai, Atsuko" sort="Jinnai, Atsuko" uniqKey="Jinnai A" first="Atsuko" last="Jinnai">Atsuko Jinnai</name><affiliation><nlm:affiliation>Department of Medicine, Tokyo Women's Medical University Medical Center East.</nlm:affiliation></affiliation></author><author><name sortKey="Kikuchi, Tomoko" sort="Kikuchi, Tomoko" uniqKey="Kikuchi T" first="Tomoko" last="Kikuchi">Tomoko Kikuchi</name></author><author><name sortKey="Ishikawa, Motonao" sort="Ishikawa, Motonao" uniqKey="Ishikawa M" first="Motonao" last="Ishikawa">Motonao Ishikawa</name></author><author><name sortKey="Nishimura, Yoshiko" sort="Nishimura, Yoshiko" uniqKey="Nishimura Y" first="Yoshiko" last="Nishimura">Yoshiko Nishimura</name></author><author><name sortKey="Shibata, Koichi" sort="Shibata, Koichi" uniqKey="Shibata K" first="Koichi" last="Shibata">Koichi Shibata</name></author><author><name sortKey="Sakura, Hiroshi" sort="Sakura, Hiroshi" uniqKey="Sakura H" first="Hiroshi" last="Sakura">Hiroshi Sakura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25142541</idno><idno type="pmid">25142541</idno><idno type="doi">10.5692/clinicalneurol.54.668</idno><idno type="wicri:Area/PubMed/Corpus">001874</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001874</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion].</title><author><name sortKey="Jinnai, Atsuko" sort="Jinnai, Atsuko" uniqKey="Jinnai A" first="Atsuko" last="Jinnai">Atsuko Jinnai</name><affiliation><nlm:affiliation>Department of Medicine, Tokyo Women's Medical University Medical Center East.</nlm:affiliation></affiliation></author><author><name sortKey="Kikuchi, Tomoko" sort="Kikuchi, Tomoko" uniqKey="Kikuchi T" first="Tomoko" last="Kikuchi">Tomoko Kikuchi</name></author><author><name sortKey="Ishikawa, Motonao" sort="Ishikawa, Motonao" uniqKey="Ishikawa M" first="Motonao" last="Ishikawa">Motonao Ishikawa</name></author><author><name sortKey="Nishimura, Yoshiko" sort="Nishimura, Yoshiko" uniqKey="Nishimura Y" first="Yoshiko" last="Nishimura">Yoshiko Nishimura</name></author><author><name sortKey="Shibata, Koichi" sort="Shibata, Koichi" uniqKey="Shibata K" first="Koichi" last="Shibata">Koichi Shibata</name></author><author><name sortKey="Sakura, Hiroshi" sort="Sakura, Hiroshi" uniqKey="Sakura H" first="Hiroshi" last="Sakura">Hiroshi Sakura</name></author></analytic><series><title level="j">Rinsho shinkeigaku = Clinical neurology</title><idno type="eISSN">1882-0654</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acyclovir (administration & dosage)</term><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (cerebrospinal fluid)</term><term>Antiviral Agents (administration & dosage)</term><term>Biomarkers (blood)</term><term>Biomarkers (cerebrospinal fluid)</term><term>Corpus Callosum (pathology)</term><term>Diffusion Magnetic Resonance Imaging</term><term>Encephalitis (drug therapy)</term><term>Encephalitis (etiology)</term><term>Encephalitis (immunology)</term><term>Encephalitis, Viral (complications)</term><term>Encephalitis, Viral (diagnosis)</term><term>Encephalitis, Viral (drug therapy)</term><term>Encephalitis, Viral (pathology)</term><term>Humans</term><term>Immunoenzyme Techniques</term><term>Immunoglobulin M (blood)</term><term>Immunoglobulin M (cerebrospinal fluid)</term><term>Infusions, Intravenous</term><term>Male</term><term>Rubella (complications)</term><term>Rubella (diagnosis)</term><term>Rubella (drug therapy)</term><term>Rubella (pathology)</term><term>Rubella virus (immunology)</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acyclovir</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Biomarkers</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Antibodies, Viral</term><term>Biomarkers</term><term>Immunoglobulin M</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Encephalitis, Viral</term><term>Rubella</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Encephalitis, Viral</term><term>Rubella</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Encephalitis</term><term>Encephalitis, Viral</term><term>Rubella</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Encephalitis</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Encephalitis</term><term>Rubella virus</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Callosum</term><term>Encephalitis, Viral</term><term>Rubella</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Diffusion Magnetic Resonance Imaging</term><term>Humans</term><term>Immunoenzyme Techniques</term><term>Infusions, Intravenous</term><term>Male</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 26-year-old male was admitted because of a fever, headache and disturbance of consciousness with lymph node swelling of the neck two days after developing a rash. A neurological examination revealed restlessness with irritability in response to sensory stimuli, such as an injection. Diffusion-weighted brain magnetic resonance imaging (MRI) revealed a hyperintense ovoid lesion in the splenium of the corpus callosum, which showed a low coefficient in the ADC map: the lesion disappeared after 22 days. An enzyme immunoassay (EIA) of the serum and cerebrospinal IgM were positive for rubella virus. The patient was therefore diagnosed with rubella encephalitis. He recovered gradually and was discharged on day 19 after the onset of symptoms without any sequelae. To our knowledge, this is the first case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). Although the exact mechanism underlying the development of rubella encephalitis is not well established, this case indicated that our patient had an immune-mediated secondary encephalitis. According to the survey of the pandemic of rubella from 2012 to April 2013 in Japan, the incidence of rubella encephalitis is thought to be relatively higher than was previously noted. This emphasizes the importance of vaccination for preventing encephalitis. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25142541</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1882-0654</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>8</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Rinsho shinkeigaku = Clinical neurology</Title><ISOAbbreviation>Rinsho Shinkeigaku</ISOAbbreviation></Journal><ArticleTitle>[A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion].</ArticleTitle><Pagination><MedlinePgn>668-70</MedlinePgn></Pagination><Abstract><AbstractText>A 26-year-old male was admitted because of a fever, headache and disturbance of consciousness with lymph node swelling of the neck two days after developing a rash. A neurological examination revealed restlessness with irritability in response to sensory stimuli, such as an injection. Diffusion-weighted brain magnetic resonance imaging (MRI) revealed a hyperintense ovoid lesion in the splenium of the corpus callosum, which showed a low coefficient in the ADC map: the lesion disappeared after 22 days. An enzyme immunoassay (EIA) of the serum and cerebrospinal IgM were positive for rubella virus. The patient was therefore diagnosed with rubella encephalitis. He recovered gradually and was discharged on day 19 after the onset of symptoms without any sequelae. To our knowledge, this is the first case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS). Although the exact mechanism underlying the development of rubella encephalitis is not well established, this case indicated that our patient had an immune-mediated secondary encephalitis. According to the survey of the pandemic of rubella from 2012 to April 2013 in Japan, the incidence of rubella encephalitis is thought to be relatively higher than was previously noted. This emphasizes the importance of vaccination for preventing encephalitis. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jinnai</LastName><ForeName>Atsuko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Tokyo Women's Medical University Medical Center East.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kikuchi</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Motonao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Koichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sakura</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Shinkeigaku</MedlineTA><NlmUniqueID>0417466</NlmUniqueID><ISSNLinking>0009-918X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4HES1O11F</RegistryNumber><NameOfSubstance UI="D000212">Acyclovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000212" MajorTopicYN="N">Acyclovir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004660" MajorTopicYN="N">Encephalitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018792" MajorTopicYN="N">Encephalitis, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012409" MajorTopicYN="N">Rubella</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012412" MajorTopicYN="N">Rubella virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25142541</ArticleId><ArticleId IdType="pii">DN/JST.JSTAGE/clinicalneurol/54.668</ArticleId><ArticleId IdType="doi">10.5692/clinicalneurol.54.668</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001874 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001874 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25142541
|texte= [A case of rubella encephalitis presenting as clinically mild encephalitis/encephalopathy with a reversible splenial lesion].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25142541" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |